Scarica l'app Stockscreener
1.56
4.00%
0.06
Dopo l'orario di chiusura:
1.56
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Precedente Chiudi:
$1.50
Aprire:
$1.5
Volume 24 ore:
483.87K
Relative Volume:
0.34
Capitalizzazione di mercato:
$252.63M
Reddito:
-
Utile/perdita netta:
$-274.18M
Rapporto P/E:
-0.6155
EPS:
-2.5346
Flusso di cassa netto:
$-198.33M
1 W Prestazione:
-1.89%
1M Prestazione:
+20.93%
6M Prestazione:
-7.69%
1 anno Prestazione:
-86.19%
Intervallo 1D:
$1.50
$1.60
Intervallo di 1 settimana:
$1.39
$1.6994
Portata 52W:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Nome
Neumora Therapeutics Inc
Settore
Industria
Telefono
(857) 760-0900
Indirizzo
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Confronta NMRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.56 | 242.92M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-07 | Downgrade | Stifel | Buy → Hold |
| 2025-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-10-10 | Iniziato | BofA Securities | Buy |
| 2023-10-10 | Iniziato | Guggenheim | Buy |
| 2023-10-10 | Iniziato | JP Morgan | Overweight |
| 2023-10-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-10 | Iniziato | Stifel | Buy |
| 2023-10-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
Federated Hermes Inc. Invests $285,000 in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
William Blair Has Positive Estimate for NMRA FY2029 Earnings - MarketBeat
Neumora's Q2 2025 Earnings Call: Unpacking Key Contradictions in M4 PAM Safety, Obesity Focus, and KOASTAL Studies - AInvest
Q3 EPS Estimate for Neumora Therapeutics Boosted by Analyst - MarketBeat
Neumora Therapeutics reports Q2 EPS (33c), consensus (37c) - MSN
Elevidys sales weaken; Neumora gets into obesity - BioPharma Dive
Neumora Therapeutics Faces Challenges as It Transitions to Full Public Company Compliance - TipRanks
Neumora Therapeutics’ Earnings Call Highlights Promising Pipeline - TipRanks
Neumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215 - MSN
Stifel maintains Hold rating on Neumora Therapeutics stock at $2.00 By Investing.com - Investing.com Canada
Promising Developments and Pipeline Progress Drive Buy Rating for Neumora Therapeutics - TipRanks
Neumora Therapeutics, Inc.: Promising Potential in Obesity Therapeutics with NMRA-215 - TipRanks
Earnings call transcript: Neumora Therapeutics beats Q2 2025 EPS estimates - Investing.com
Neumora Therapeutics Reports Q2 2025 Financial Results - TipRanks
Neumora Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Neumora Targets $180B Obesity Market with New Brain-Penetrant Drug, Reports 6 Clinical Readouts Coming - Stock Titan
Neumora Therapeutics to Report Q2 2025 Financial Results on August 6, 2025 - AInvest
Neumora Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
How volatile is Neumora Therapeutics Inc. stock compared to the marketUnprecedented market success - Jammu Links News
Why is Neumora Therapeutics Inc. stock attracting strong analyst attentionSignificant capital appreciation - Jammu Links News
Does Neumora Therapeutics Inc. stock perform well during market downturnsCapitalize on fast-growing stocks today - Jammu Links News
How does Neumora Therapeutics Inc. generate profit in a changing economyCapitalize on market trends with expert guidance - Jammu Links News
Is it the right time to buy Neumora Therapeutics Inc. stockFree Trading Psychology Coaching - Jammu Links News
What institutional investors are buying Neumora Therapeutics Inc. stockAchieve triple-digit returns with smart investing - Jammu Links News
What are the latest earnings results for Neumora Therapeutics Inc.Capitalize on market momentum for maximum profit - Jammu Links News
What are analysts’ price targets for Neumora Therapeutics Inc. in the next 12 monthsAI Powered Tips With High Returns - Jammu Links News
Neumora Therapeutics (NMRA) Projected to Post Earnings on Wednesday - MarketBeat
How strong is Neumora Therapeutics Inc. company’s balance sheetExpert Picks Entry Points For 2025 - Jammu Links News
What is the dividend policy of Neumora Therapeutics Inc. stockPost Market Planner That Work - Jammu Links News
How many analysts rate Neumora Therapeutics Inc. as a “Buy”Chart Pattern Updates For Fast Growth - Jammu Links News
What are the technical indicators suggesting about Neumora Therapeutics Inc.Chart Pattern Guidance To Watch Now - Jammu Links News
Key metrics from Neumora Therapeutics Inc.’s quarterly dataTrade Insight With Community Collaboration Supported - metal.it
What are Neumora Therapeutics Inc. company’s key revenue driversAI Powered Planner Backed By Experts - Jammu Links News
Why Neumora Therapeutics Inc. stock attracts strong analyst attentionStrong Buy With Technical Confidence Supported - beatles.ru
Published on: 2025-07-30 12:15:41 - metal.it
Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating - MSN
Mizuho Boosts Neumora Price Target to $5, Maintains Outperform Rating - AInvest
Pegasystems Delivers Strong Q2 Results, Raises Price Target to $58 - AInvest
Published on: 2025-07-29 01:24:00 - metal.it
What is Neumora Therapeutics Inc. company’s growth strategyNavigate market volatility with smart strategies - jammulinksnews.com
When is Neumora Therapeutics Inc. stock expected to show significant growthCapitalize on market trends with expert guidance - Jammu Links News
Neumora Therapeutics Inc Azioni (NMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):